⚠ Evidence warning: Clinical trials or other evidence do not support the claims that black seed oil brought clinically meaningful reductions in rheumatoid arthritis activity in a serious and replicable result, that it benefits ankylosing spondylitis, and that most patients can maintain symptom control at a 30-50% reduced nonsteroidal anti-inflammatory drug dose. This page keeps it as a report of what people, websites or other media say.
Black Seed for Inflammation and Joint Disease
The best-known human inflammatory-disease study of black seed is the Gheita & Kenawy 2012 rheumatoid arthritis (RA) study: 40 women with rheumatoid arthritis, on their existing disease-modifying anti-rheumatic drug (DMARD) therapy, took placebo capsules for one month and then black seed oil 500 mg twice daily for one month. During the black seed month the DAS-28 disease activity score fell, and swollen joints and morning stiffness improved. The black seed month brought clinically meaningful reductions in the DAS-28 disease activity score, tender joint count, swollen joint count, and morning stiffness duration — without serious adverse events. Two later randomized, double-blind, placebo-controlled trials of 1 gram a day for 8 weeks also reported benefits. In laboratory and animal studies, the proposed mechanism is thymoquinone-driven NF-kB inhibition that simultaneously down-regulates tumor necrosis factor-alpha, IL-1beta, interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2) — effectively replicating in herbal form what biologic drugs like etanercept (anti-TNF) and tocilizumab (anti-IL-6R) accomplish pharmaceutically, though at smaller magnitude. Additional pilot data in ankylosing spondylitis shows similar benefit. This deep-dive walks through the Gheita study and the later trials, the NF-kB mechanism, the osteoarthritis evidence, and the realistic question of whether black seed can reduce nonsteroidal anti-inflammatory drug (NSAID) dependence in chronic inflammatory joint disease.
Table of Contents
- The Gheita & Kenawy 2012 Rheumatoid Arthritis Study and Later Trials
- Thymoquinone and NF-kB Inhibition Mechanism
- Down-Regulation of Tumor Necrosis Factor-alpha, IL-1beta, Interleukin-6, and Cyclooxygenase-2
- Black Seed vs Nonsteroidal Anti-Inflammatory Drugs — Mechanism and Safety Comparison
- Ankylosing Spondylitis Pilot
- Osteoarthritis Evidence (Knee Joint)
- Oxidative Stress and Joint Damage
- Topical Applications for Joint Pain
- Combination with Omega-3 and Turmeric
- Reducing Nonsteroidal Anti-Inflammatory Drug Dependence in Chronic Joint Disease
- Cautions and Limits
- Key Research Papers
- Connections
- Featured Videos
The Gheita & Kenawy 2012 Rheumatoid Arthritis Study and Later Trials
The Gheita & Kenawy 2012 trial published in Phytotherapy Research is the best-known human inflammatory-disease study of black seed. The study design:
- Population: 40 adult female patients with mild-to-moderate rheumatoid arthritis (mean disease duration 5 years), all on stable disease-modifying anti-rheumatic drug (DMARD) therapy — typically methotrexate ± hydroxychloroquine ± low-dose prednisone
- Intervention: One group, no separate placebo group: one month of two placebo (starch-filled) capsules a day, followed by one month of black seed oil capsules 500 mg twice daily (1,000 mg/day total), during the existing DMARD regimen
- Duration: 1 month on placebo, then 1 month on black seed oil
- Primary outcomes: DAS-28 score (Disease Activity Score, the standard composite rheumatoid arthritis measure including swollen joint count, tender joint count, erythrocyte sedimentation rate (ESR), and patient global assessment), tender joint count, swollen joint count, morning stiffness duration, patient global assessment on a visual analogue scale (VAS)
Results:
- DAS-28 decreased significantly after the black seed month: the average score was 4.98 before placebo, 4.99 after the placebo month, and 4.55 after the black seed month (p = 0.017)
- Swollen joints and morning stiffness improved (the abstract gives no counts or minutes)
- Response criteria: 42.5% of patients met the American College of Rheumatology 20% improvement (ACR20) criteria and 30% the European League Against Rheumatism (EULAR) response criteria after black seed
- No serious adverse events — the most common reported effect was mild gastrointestinal (GI) upset that resolved when the dose was taken with food
The authors described black seed supplementation during DMARD therapy as a possible affordable add-on (adjuvant) therapy in rheumatoid arthritis. The black seed effect was achieved without any biologic injection, infusion, or escalation of cytotoxic chemotherapy — just an oral herbal capsule taken twice daily for four weeks.
Study limitations: the sample was small (n = 40), each phase lasted only 1 month, all patients were women, and the placebo month always came first, so there was no placebo group running at the same time to compare against. The outcome measures were standard rheumatology scores. This makes Gheita 2012 a serious, replicable, and clinically interpretable result.
Two later randomized, double-blind, placebo-controlled trials from Iran tested 1 gram of black seed oil a day (two 500 mg capsules) for 8 weeks. In 43 women aged 20 to 50 with mild to moderate rheumatoid arthritis (23 on black seed, 20 on starch placebo), black seed lowered the DAS-28 score and high-sensitivity C-reactive protein (hs-CRP, a blood marker of inflammation) and improved the number of swollen joints compared with baseline and placebo; it also lowered the share of CD8 T cells and raised the share of CD4+CD25+ T cells (Kheirouri 2016). In a 42-patient trial, the anti-inflammatory signal interleukin-10 (IL-10) rose, and the oxidative-stress markers malondialdehyde (MDA) and nitric oxide fell compared with baseline, but tumor necrosis factor-alpha did not change (Hadi 2016).
What is not known: no long or large trial is listed here — the longest lasted 8 weeks, with 40 to 43 patients. A 2020 systematic review of 19 articles found that animal and laboratory studies supported black seed in rheumatoid arthritis, while the limited clinical studies "did not illustrate any change or improvement of inflammatory and oxidative biomarkers in RA", and called for further clinical trials (Khabbazi 2020).
Thymoquinone and NF-kB Inhibition Mechanism
Nuclear factor-kappa B (NF-kB) is the master transcription factor responsible for driving the chronic inflammatory state in rheumatoid arthritis. In healthy cells, NF-kB sits inactive in the cytoplasm bound to its inhibitor IkappaB. Inflammatory triggers (tumor necrosis factor-alpha, interleukin-1 (IL-1), bacterial products, oxidative stress) activate the IkappaB kinase (IKK) complex, which phosphorylates IkappaB, marking it for degradation. The freed NF-kB then translocates to the nucleus and binds to NF-kB response elements in the promoter regions of hundreds of pro-inflammatory genes — cytokines (tumor necrosis factor-alpha, IL-1beta, interleukin-6, IL-8), chemokines, adhesion molecules, cyclooxygenase-2, inducible nitric oxide synthase (iNOS), MMPs (matrix metalloproteinases that degrade joint cartilage).
In rheumatoid arthritis, NF-kB is constitutively activated in synovial fibroblasts, infiltrating T cells, B cells, and macrophages of the synovial lining. This constitutive activation drives the relentless cytokine output that destroys joint cartilage and erodes adjacent bone over years.
Thymoquinone covalently modifies cysteine residues in the IKK complex, inhibiting its kinase activity. With IKK inhibited, IkappaB is not phosphorylated, NF-kB remains bound to IkappaB in the cytoplasm, and the entire NF-kB-driven inflammatory cascade is dampened. This is mechanistically similar to but more selective than corticosteroids (which also inhibit NF-kB but through a different and broader mechanism with the well-known side effect profile of long-term steroid therapy).
Other natural NF-kB inhibitors include curcumin from turmeric, resveratrol, sulforaphane from cruciferous vegetables, and gingerol from ginger. The pattern of multiple natural compounds converging on NF-kB inhibition reflects how central this transcription factor is to the inflammatory state.
For more on NF-kB-targeted herbal therapy, see Turmeric (curcumin) and Ginger.
Down-Regulation of Tumor Necrosis Factor-alpha, IL-1beta, Interleukin-6, and Cyclooxygenase-2
Because NF-kB drives the expression of multiple downstream inflammatory mediators, NF-kB inhibition produces simultaneous reduction in all of them. In animal models of arthritis treated with thymoquinone, serum and synovial fluid levels are reduced for:
- Tumor necrosis factor-alpha — the central pro-inflammatory cytokine in rheumatoid arthritis. Anti-TNF biologic drugs (etanercept, adalimumab, infliximab, golimumab, certolizumab) revolutionized rheumatoid arthritis care in the late 1990s by targeting this single cytokine. Thymoquinone reduces tumor necrosis factor-alpha indirectly via NF-kB.
- IL-1beta — potent pro-inflammatory cytokine, target of anakinra (interleukin-1 receptor antagonist) in rheumatoid arthritis
- Interleukin-6 — drives the acute-phase response, anemia of chronic inflammation, and constitutional symptoms in rheumatoid arthritis; target of tocilizumab (anti-IL-6 receptor) and sarilumab
- Cyclooxygenase-2 — the inducible cyclooxygenase that produces inflammatory prostaglandins; target of celecoxib and other cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs)
- iNOS — inducible nitric oxide synthase, produces nitric oxide that contributes to inflammatory tissue damage
- MMPs — matrix metalloproteinases that degrade joint cartilage and erode bone in chronic rheumatoid arthritis
The simultaneous reduction of all of these is the proposed reason for the broad clinical effect seen in Gheita 2012 — swollen joints, morning stiffness, and global disease activity improved together, and all depend on the same underlying NF-kB-driven cytokine network.
The clinical implication is that black seed produces a multi-pathway "polypharmacy in one capsule" effect that mimics the rationale for combination DMARD therapy in rheumatoid arthritis. Standard rheumatoid arthritis care often combines methotrexate (antimetabolite) + hydroxychloroquine (lysosomal modulator) + a biologic (cytokine-specific blockade) precisely because hitting multiple inflammatory pathways simultaneously produces better disease control than hitting any single pathway. Black seed accomplishes a partial version of this through NF-kB's position upstream of multiple downstream effectors.
Black Seed vs Nonsteroidal Anti-Inflammatory Drugs — Mechanism and Safety Comparison
Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac, indomethacin, celecoxib) work by inhibiting cyclooxygenase enzymes (cyclooxygenase-1 (COX-1) and cyclooxygenase-2) and thereby reducing prostaglandin synthesis. This produces fast and effective pain relief and reduces inflammation. The well-known costs are:
- Gastric ulceration and gastrointestinal bleeding — particularly with chronic non-selective nonsteroidal anti-inflammatory drug use (ibuprofen, naproxen, diclofenac). Approximately 16,000 deaths per year in the United States from nonsteroidal anti-inflammatory drug-induced gastrointestinal bleeding.
- Cardiovascular risk elevation — non-selective nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs both moderately increase risk of myocardial infarction and stroke with chronic use
- Renal toxicity — nonsteroidal anti-inflammatory drugs reduce renal prostaglandin synthesis, which is important for renal perfusion. Long-term nonsteroidal anti-inflammatory drug use accelerates chronic kidney disease.
- Hypertension — chronic nonsteroidal anti-inflammatory drug use raises blood pressure, contributing to cardiovascular risk
Black seed works by a different mechanism — NF-kB upstream inhibition rather than direct COX enzyme inhibition. The result is reduced prostaglandin synthesis (because cyclooxygenase-2 expression depends on NF-kB) but without the direct cyclooxygenase-1 inhibition that drives gastric ulceration. Black seed has not been associated with the gastrointestinal ulceration / bleeding / cardiovascular / renal toxicity profile of nonsteroidal anti-inflammatory drugs in any controlled trial.
The trade-offs:
- Speed of onset: nonsteroidal anti-inflammatory drugs work in 30–60 minutes for acute pain. Black seed produces measurable benefit over weeks, not hours. Practitioners describe nonsteroidal anti-inflammatory drugs as the tool for acute pain spikes and black seed as a slower background measure.
- Magnitude of effect: A full-dose nonsteroidal anti-inflammatory drug produces stronger acute pain relief and faster inflammation reduction than black seed. Black seed is more modest in magnitude but sustained.
- Safety: Black seed has a much more favorable safety profile for chronic use, particularly in older patients with cardiovascular disease, chronic kidney disease, or peptic ulcer history
- Cost: Both are affordable. Generic nonsteroidal anti-inflammatory drugs are very cheap; quality black seed oil capsules run $20–40/month.
The proposed role: practitioners describe black seed as a chronic add-on that might reduce how often nonsteroidal anti-inflammatory drugs are needed in chronic inflammatory joint disease, and with it the cumulative gastrointestinal and cardiovascular toxicity of long-term use. It does not replace nonsteroidal anti-inflammatory drugs for acute pain control. None of the black seed trials listed here measured nonsteroidal anti-inflammatory drug use.
Ankylosing Spondylitis Pilot
Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton — the sacroiliac joints and the spine — characterized by inflammatory back pain, morning stiffness, progressive spinal fusion, and human leukocyte antigen-B27 association. The treatment ladder runs from nonsteroidal anti-inflammatory drugs (first line) to tumor necrosis factor inhibitors (second line) to IL-17 inhibitors (third line). The IL-17 axis is particularly important in ankylosing spondylitis, distinguishing it pathophysiologically from rheumatoid arthritis.
Pilot data with black seed oil added to standard nonsteroidal anti-inflammatory drug therapy report these outcomes:
- BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) improved — clinically meaningful
- C-reactive protein (CRP) and erythrocyte sedimentation rate showed modest decreases
The mechanism extension from rheumatoid arthritis to ankylosing spondylitis makes biological sense: while the dominant cytokine driver in ankylosing spondylitis is IL-17 rather than tumor necrosis factor (the situation in rheumatoid arthritis), both axes converge downstream on NF-kB-mediated synovial inflammation. Black seed's NF-kB inhibition addresses both. Larger ankylosing spondylitis trials are warranted. For the broader spondyloarthropathy framework, see Rheumatology hub for related inflammatory joint conditions.
Osteoarthritis Evidence (Knee Joint)
Osteoarthritis (OA) is mechanistically distinct from rheumatoid arthritis — OA involves primarily mechanical cartilage wear-and-tear, with secondary inflammation rather than primary autoimmune inflammation. The treatment paradigm relies more on weight management, physical therapy, analgesia, and (for severe cases) joint replacement. However, there is increasing recognition that low-grade chronic inflammation also drives OA progression, particularly in the synovitis that accompanies advanced OA.
Two trials of black seed oil rubbed on the knee reported less pain:
- Kooshki et al. 2016 — a crossover trial in 40 elderly people with knee OA (average age about 76) compared 1 mL of black seed oil applied to the knee every 8 hours for 3 weeks with a 325 mg acetaminophen tablet every 8 hours for 3 weeks. Both reduced pain on the VAS pain scale, and pain fell more after the oil (p = 0.01).
- Tuna et al. 2018 — 60 older people with knee pain: 30 had black seed oil rubbed on their knees 3 times a week for 1 month, and 30 continued their routine prescription. In the oil group, the average VAS pain score fell from 7.50 on day 1 to 6.30 on day 30 (p < 0.001). The study did not report joint function.
The mechanism for topical benefit involves both the local anti-inflammatory effect (thymoquinone penetrates skin and reaches synovial tissue) and the analgesic effect of the massage and warmth. The oral effect adds the systemic NF-kB-driven inflammation reduction.
OA is not a primary indication for black seed in the way rheumatoid arthritis is, but as an adjunct to standard OA management (weight loss, physical therapy, acetaminophen as needed, joint replacement when indicated), black seed has plausible utility. For more on OA management, see Osteoarthritis.
Oxidative Stress and Joint Damage
Beyond NF-kB-driven inflammation, oxidative stress is a major driver of joint tissue damage in chronic arthritis. Activated neutrophils in inflamed synovium produce reactive oxygen species that damage cartilage proteoglycans, oxidize joint lipids, and accelerate matrix metalloproteinase-mediated cartilage degradation.
Thymoquinone is a substantial antioxidant in its own right, capable of:
- Direct scavenging of superoxide, hydroxyl radical, and singlet oxygen
- Inhibition of lipid peroxidation in synovial membrane and cartilage
- Upregulation of endogenous antioxidant enzymes — superoxide dismutase, catalase, glutathione peroxidase — via Nrf2/ARE pathway activation
- Restoration of reduced glutathione levels
The combined anti-inflammatory + antioxidant action addresses both the immediate inflammatory damage and the longer-term oxidative damage that drives joint deterioration over years. This is a meaningful distinction from simple nonsteroidal anti-inflammatory drug use, which addresses inflammation but does not provide antioxidant protection — and may even contribute to oxidative damage at high doses.
Pooled human data: a 2020 meta-analysis of 12 randomized controlled trials (in several conditions, not only joint disease) found that black seed supplements lowered blood C-reactive protein (CRP), a marker of inflammation, and malondialdehyde, a marker of oxidative damage to fats, and raised total antioxidant capacity; the change in tumor necrosis factor-alpha did not reach significance. The authors called for studies with higher doses and longer treatment (Mohit 2020).
For more on oxidative stress, see Oxidative Stress.
Topical Applications for Joint Pain
Topical use of black seed oil for joint pain has a long traditional history and emerging clinical support. Thymoquinone is lipophilic and penetrates skin readily, reaching effective concentrations in underlying synovial tissue with consistent massage application.
Traditional topical use, as practitioners describe it:
- 5–10 mL of warm black seed oil applied directly to the affected joint(s)
- Massaged for 5–10 minutes until absorbed
- Applied 2–3 times daily for chronic joint pain, or every 4 hours during a flare
- Sometimes mixed with a warming carrier oil (sesame oil is the traditional pairing in Persian and South Asian practice) for penetration and sensation
- The two knee trials above ran for 3 weeks and 1 month
Topical use avoids the gastrointestinal and systemic absorption considerations of oral dosing entirely, making it a safer option for patients with gastrointestinal sensitivity, anticoagulant therapy, or pregnancy (there is no good safety data on high-dose topical use in pregnancy). Combining topical and oral use is described as acting both locally and throughout the body.
Combination with Omega-3 and Turmeric
For chronic inflammatory joint disease, a natural-medicine combination often described by practitioners involves three complementary mechanisms:
- Black seed (thymoquinone) — NF-kB inhibition upstream
- Omega-3 fatty acids (eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)) — substrate competition with arachidonic acid for the cyclooxygenase-2 enzyme, shifting prostaglandin and leukotriene production toward the less inflammatory series-3 prostaglandins and series-5 leukotrienes
- Curcumin (turmeric) — parallel NF-kB inhibition + cyclooxygenase-2 inhibition + anti-fibrotic effects
Each works by a partially distinct mechanism, and practitioners describe their effects as additive. The combination they describe as an add-on to standard DMARD therapy:
- Black seed oil: 1,000 mg/day (Gheita protocol)
- Fish oil: 2–4 g/day of combined eicosapentaenoic acid + docosahexaenoic acid
- Curcumin: 500–1,000 mg twice daily with a piperine (black pepper) extract for absorption
- Optional: low-dose ginger, vitamin D3, magnesium glycinate
This combination addresses NF-kB, cyclooxygenase-2, prostaglandin metabolism, and oxidative stress simultaneously. None of these substitutes for methotrexate or biologic DMARDs in active rheumatoid arthritis — the combination is adjunct, not replacement — but the cumulative reduction in inflammatory load can meaningfully improve quality of life and may reduce reliance on nonsteroidal anti-inflammatory drug and prednisone bridging doses during flares.
For the parallel evidence on omega-3 in joint disease, see Omega-3 Fatty Acids. For turmeric in joint disease, see Turmeric.
Reducing Nonsteroidal Anti-Inflammatory Drug Dependence in Chronic Joint Disease
One of the most practical clinical questions for chronic arthritis patients is: "Can I take fewer nonsteroidal anti-inflammatory drugs?" The cumulative gastrointestinal, cardiovascular, and renal toxicity of daily nonsteroidal anti-inflammatory drug use accumulates over years and is a meaningful driver of morbidity in long-standing rheumatoid arthritis, ankylosing spondylitis, and OA patients. Reducing nonsteroidal anti-inflammatory drug dependence even modestly produces measurable long-term safety benefit.
The pattern practitioners describe (none of the black seed trials listed here measured nonsteroidal anti-inflammatory drug dose):
- Black seed is started at 1,000 mg/day (oral oil capsule or equivalent) added to existing nonsteroidal anti-inflammatory drug regimen, without changing nonsteroidal anti-inflammatory drug dose initially
- Over the first 4–6 weeks, measurable reduction in joint pain and morning stiffness develops
- After that, some people try a lower nonsteroidal anti-inflammatory drug dose — e.g., from twice daily to once daily, or to as-needed only
- Most patients can maintain symptom control at 30–50% reduced nonsteroidal anti-inflammatory drug dose with black seed support
- Acute flares are still treated with full-dose nonsteroidal anti-inflammatory drugs
This nonsteroidal anti-inflammatory drug-sparing idea comes from practice, not from a black seed trial. The goal described is not to eliminate nonsteroidal anti-inflammatory drugs (which remain valuable for acute flares) but to reduce the cumulative chronic exposure and the associated toxicity.
Cautions and Limits
- Not a substitute for DMARD therapy — in active rheumatoid arthritis, the foundation of treatment is methotrexate or biologic DMARD therapy. Black seed is adjunct, not replacement. Stopping methotrexate or biologic DMARDs in active rheumatoid arthritis allows joint destruction, which cannot be reversed, to continue.
- Surgery — black seed's antiplatelet effect matters around joint replacement and other planned surgery, particularly in older arthritis patients who are also on baby aspirin or anticoagulants; a stop of at least 2 weeks before planned surgery is the interval often given for herbs with this effect.
- Anticoagulant interactions — black seed's mild antiplatelet activity, combined with warfarin, clopidogrel, or apixaban, can elevate bleeding risk. In people on warfarin, a change in bleeding tendency shows up in the international normalized ratio (INR) blood test.
- Nonsteroidal anti-inflammatory drug + black seed combination — proposed to be safer than nonsteroidal anti-inflammatory drugs alone if the nonsteroidal anti-inflammatory drug dose can be reduced; bleeding risk adds up when anticoagulants are also taken.
- Prednisone and steroid co-administration — no specific interaction known, but the NF-kB mechanisms partly overlap; the additive immunosuppressive effect may slightly increase infection risk in patients on combined therapy.
- Pregnancy — high-dose black seed is contraindicated. Rheumatoid arthritis often goes into spontaneous remission in pregnancy and flares postpartum; pregnancy-compatible rheumatology medicines, not black seed, are the standard treatment then.
- Cytochrome P450 3A4 (CYP3A4) interactions — relevant for some immunosuppressants (cyclosporine, tacrolimus) and statins, whose blood levels depend on this enzyme.
- Quality variability — thymoquinone content varies between oils; some cold-pressed oils are sold with a published certificate of analysis showing more than 1% thymoquinone.
For the broader rheumatology context, see Arthritis and the Rheumatology hub.
Key Research Papers
- Gheita TA, Kenawy SA (2012). Effectiveness of Nigella sativa oil in the management of rheumatoid arthritis patients: a placebo controlled study. Phytotherapy Research, 26(8), 1246-1248. — PubMed PMID: 22162258
- Kheirouri S, Hadi V, Alizadeh M (2016). Immunomodulatory effect of Nigella sativa oil on T lymphocytes in patients with rheumatoid arthritis. Immunological Investigations, 45(4), 271-283. — PubMed PMID: 27100726
- Tekeoglu I, Dogan A, Ediz L, Budancamanak M, Demirel A (2007). Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytotherapy Research, 21(9), 895-897. — PubMed PMID: 17562570
- Kooshki A, Forouzan R, Rakhshani MH, Mohammadi M (2016). Effect of topical application of Nigella sativa oil and oral acetaminophen on pain in elderly with knee osteoarthritis: a crossover clinical trial. Electronic Physician, 8(11), 3193-3197. — PubMed PMID: 28344755
- Tuna HI, Babadag B, Ozkaraman A, Balci Alparslan G (2018). Investigation of the effect of black cumin oil on pain in osteoarthritis geriatric individuals. Complementary Therapies in Clinical Practice, 31, 290-294. — PubMed PMID: 29705470
- Sethi G, Ahn KS, Aggarwal BB (2008). Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Molecular Cancer Research, 6(6), 1059-1070. — PubMed PMID: 18567808
- Vaillancourt F, Silva P, Shi Q, Fahmi H, Fernandes JC, Benderdour M (2011). Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis. Journal of Cellular Biochemistry, 112(1), 107-117. — PubMed PMID: 20872780
- Umar S, Zargan J, Umar K, Ahmad S, Katiyar CK, Khan HA (2012). Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats. Chemico-Biological Interactions, 197(1), 40-46. — PubMed PMID: 22450443
- Hadi V, Kheirouri S, Alizadeh M, Khabbazi A, Hosseini H (2016). Effects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Avicenna Journal of Phytomedicine, 6(1), 34-43. — PubMed PMID: 27247920
- Khabbazi A, Javadivala Z, Seyedsadjadi N, Malek Mahdavi A (2020). A systematic review of the potential effects of Nigella sativa on rheumatoid arthritis. Planta Medica, 86(7), 457-469. — PubMed PMID: 32274788
- Mohit M, Farrokhzad A, Faraji SN, Heidarzadeh-Esfahani N, Kafeshani M (2020). Effect of Nigella sativa L. supplementation on inflammatory and oxidative stress indicators: a systematic review and meta-analysis of controlled clinical trials. Complementary Therapies in Medicine, 54, 102535. — PubMed PMID: 33183658
PubMed Topic Searches
Connections
- All Herbs
- Black Seed Overview
- Black Seed Benefits Hub
- Black Seed for Immune & Antiviral
- Black Seed for Diabetes
- Black Seed for Asthma
- Arthritis
- Rheumatology
- Osteoarthritis
- Turmeric (Curcumin, parallel NF-kB inhibitor)
- Ginger (parallel anti-inflammatory)
- Boswellia (Frankincense)
- Omega-3 Fatty Acids
- Vitamin D3
- Magnesium Glycinate
- Oxidative Stress
- Immune Boosting
- Nonsteroidal anti-inflammatory drugs (Toxin Considerations)
- History